Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 146 No. 4950 (2016)

Connexins and pannexins: from biology towards clinical targets

  • Paolo Meda
  • Jacques-Antoine Haefliger
DOI
https://doi.org/10.4414/smw.2016.14365
Cite this as:
Swiss Med Wkly. 2016;146:w14365
Published
04.12.2016

Summary

Efficient cell communication is a prerequisite for the coordinated function of tissues and organs. In vertebrates, this communication is mediated by a variety of mechanisms, including the exchange of molecules between cells, and between cells and the extracellular medium, via membrane channels made of connexin and pannexin proteins. These channels are a necessary component of all human tissues. Here, we review the biological essentials of the connexin and pannexin families, and the roles of these proteins in the function of cells which are central to major human diseases. We then discuss how connexins and pannexins participate in human pathology, and the clinical perspectives that this knowledge opens.

References

  1. Bull L. On the evolution of multicelluarity and eusociality. Artif Life. 1999;5(1):1–15.
  2. Michod RE, Roze D. Cooperation and conflict in the evolution of multicellularity. Heredity. 2001;86(Pt 1):1–7.
  3. Edelman GM. Cell adhesion and the molecular processes of morphogenesis. Annu Rev Biochem. 1985;54:135–69.
  4. LeRoith D, Delahunty G, Wilson GL, Roberts CT, Jr., Shemer J, Hart C, et al. Evolutionary aspects of the endocrine and nervous systems. Recent Prog HormRes. 1986;42:549–87.
  5. Bosco D, Haefliger JA, Meda P. Connexins: key mediators of endocrine function. Physiol Rev. 2011;91(4):1393–445.
  6. Esseltine JL, Laird DW. Next-generation connexin and pannexin cell biology. Trends Cell Biol. 2016.S0962-8924(16)30074-5. [Epub ahead of print]
  7. Scemes E, Spray DC, Meda P. Connexins, pannexins, innexins: novel roles of “hemi-channels”. Pflugers Arch. 2009;457(6):1207–26.
  8. Wingard JC, Zhao HB. Cellular and deafness mechanisms underlying connexin mutation-induced hearing loss – a common hereditary deafness. Front Cel Neurosci. 2015;9:202.
  9. Pfenniger A, Wohlwend A, Kwak BR. Mutations in connexin genes and disease. Eur J Clin Invest. 2011;41(1):103–16.
  10. Lilly E, Sellitto C, Milstone LM, White TW. Connexin channels in congenital skin disorders. Semin Cell Dev Biol. 2016;50:4–12.
  11. Cigliola V, Populaire C, Pierri CL, Deutsch S, Haefliger JA, Fadista J, et al. A variant of GJD2, encoding for connexin 36, alters the function of insulin producing beta-cells. PLoS One. 2016;11(3):e0150880.
  12. Mas C, Taske N, Deutsch S, Guipponi M, Thomas P, Covanis A, et al. Association of the connexin36 gene with juvenile myoclonic epilepsy. J Med Genet. 2004;41(7):e93.
  13. Penuela S, Harland L, Simek J, Laird DW. Pannexin channels and their links to human disease. Biochem J. 2014;461(3):371–81.
  14. Retamal MA, Reyes EP, Garcia IE, Pinto B, Martinez AD, Gonzalez C. Diseases associated with leaky hemichannels. Front Cell Neurosci. 2015;9:267.
  15. Klee P, Allagnat F, Pontes H, Cederroth M, Charollais A, Caille D, et al. Connexins protect mouse pancreatic beta cells against apoptosis. J Clin Invest. 2011;121(12):4870–9.
  16. Cigliola V, Allagnat F, Berchtold LA, Lamprianou S, Haefliger JA, Meda P. Role of connexins and pannexins in the pancreas. Pancreas. 2015;44(8):1234–44.
  17. Furlow PW, Zhang S, Soong TD, Halberg N, Goodarzi H, Mangrum C, et al. Mechanosensitive pannexin-1 channels mediate microvascular metastatic cell survival. Nat Cell Biol. 2015;17(7):943–52.
  18. Head WS, Orseth ML, Nunemaker CS, Satin LS, Piston DW, Benninger RK. Connexin-36 gap junctions regulate in vivo first- and second-phase insulin secretion dynamics and glucose tolerance in the conscious mouse. Diabetes. 2012;61(7):1700–7.
  19. Haefliger JA, Martin D, Favre D, Petremand Y, Mazzolai L, Abderrahmani A, et al. Reduction of connexin36 content by ICER-1 contributes to insulin-secreting cells apoptosis induced by oxidized LDL particles. PLoS One. 2013;8(1):e55198.
  20. Hodson DJ, Mitchell RK, Bellomo EA, Sun G, Vinet L, Meda P, et al. Lipotoxicity disrupts incretin-regulated human beta cell connectivity. J Clin Invest. 2013;123(10):4182–94.
  21. Allagnat F, Klee P, Cardozo AK, Meda P, Haefliger JA. Connexin36 contributes to INS-1E cells survival through modulation of cytokine-induced oxidative stress, ER stress and AMPK activity. Cell Death Differ. 2013;20(12):1742–52.
  22. Kurtz A. Connexins, renin cell displacement and hypertension. Curr Opin Pharmacol. 2015;21:1–6.
  23. Le Gal L, Alonso F, Wagner C, Germain S, Nardelli Haefliger D, Meda P, et al. Restoration of connexin 40 (Cx40) in renin-producing cells reduces the hypertension of Cx40 null mice. Hypertension. 2014;63(6):1198–204.
  24. Simon AM, Goodenough DA, Li E, Paul DL. Female infertility in mice lacking connexin 37. Nature. 1997;385(6616):525–9.
  25. Wagner C, Kurtz L, Schweda F, Simon AM, Kurtz A. Connexin 37 is dispensable for the control of the renin system and for positioning of renin-producing cells in the kidney. Pflugers Arch. 2009;459(1):151–8.
  26. Haefliger JA, Krattinger N, Martin D, Pedrazzini T, Capponi A, Doring B, et al. Connexin43-dependent mechanism modulates renin secretion and hypertension. J Clin Invest. 2006;116(2):405–13.
  27. Abed AB, Kavvadas P, Chadjichristos CE. Functional roles of connexins and pannexins in the kidney. Cell Mol Life Sci. 2015;72(15):2869–77.
  28. Jobs A, Schmidt K, Schmidt VJ, Lubkemeier I, van Veen TA, Kurtz A, et al. Defective Cx40 maintains Cx37 expression but intact Cx40 is crucial for conducted dilations irrespective of hypertension. Hypertension. 2012;60(6):1422–9.
  29. Alonso F, Krattinger N, Mazzolai L, Simon A, Waeber G, Meda P, et al. An angiotensin II- and NF-kappaB-dependent mechanism increases connexin 43 in murine arteries targeted by renin-dependent hypertension. Cardiovasc Res. 2010;87(1):166–76.
  30. Alonso F, Boittin FX, Beny JL, Haefliger JA. Loss of connexin40 is associated with decreased endothelium-dependent relaxations and eNOS levels in the mouse aorta. Am J Physiol Heart Circ Physiol. 2010;299(5):H1365–73.
  31. Le Gal L, Alonso F, Mazzolai L, Meda P, Haefliger JA. Interplay between connexin40 and nitric oxide signaling during hypertension. Hypertension. 2015;65(4):910–5.
  32. Koenigsberger M, Seppey D, Beny JL, Meister JJ. Mechanisms of propagation of intercellular calcium waves in arterial smooth muscle cells. Biophys J. 2010;99(2):333–43.
  33. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011;91(3):1071–121.
  34. Fukumura D, Duda DG, Munn LL, Jain RK. Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation. 2010;17(3):206–25.
  35. Choudhary M, Naczki C, Chen W, Barlow KD, Case LD, Metheny-Barlow LJ. Tumor-induced loss of mural Connexin 43 gap junction activity promotes endothelial proliferation. BMC Cancer. 2015;15:427.
  36. Alonso F, Domingos-Pereira S, Le Gal L, Derre L, Meda P, Jichlinski P, et al. Targeting endothelial connexin40 inhibits tumor growth by reducing angiogenesis and improving vessel perfusion. Oncotarget. 2016;7(12):14015–28.
  37. Pfenniger A, Derouette JP, Verma V, Lin X, Foglia B, Coombs W, et al. Gap junction protein Cx37 interacts with endothelial nitric oxide synthase in endothelial cells. Arterioscler Thromb Vasc Biol. 2010;30(4):827–34.
  38. Wang WK, Chen MC, Leong HF, Kuo YL, Kuo CY, Lee CH. Connexin 43 suppresses tumor angogenesis by down-regulation of vascular endothelial growth factor via hypoxic-induced factor-1alpha. Int J Mol Sci. 2015;16(1):439–51.
  39. Jiang JX, Penuela S. Connexin and pannexin channels in cancer. BMC cell biology. 2016;17(Suppl 1):12.
  40. Lamprianou S, Gysemans C, Bou Saab J, Pontes H, Mathieu C, Meda P. Glibenclamide prevents diabetes in NOD mice, PLos One 2016, in press.
  41. Lubkemeier I, Machura K, Kurtz L, Neubauer B, Dobrowolski R, Schweda F, et al. The connexin 40 A96S mutation causes renin-dependent hypertension. J Am Soc Nephrol. 2011;22(6):1031–40.
  42. Firouzi M, Kok B, Spiering W, Busjahn A, Bezzina CR, Ruijter JM, et al. Polymorphisms in human connexin40 gene promoter are associated with increased risk of hypertension in men. J Hypertens. 2006;24(2):325–30.
  43. van Dillen IJ, Mulder NH, Vaalburg W, de Vries EF, Hospers GA. Influence of the bystander effect on HSV-tk/GCV gene therapy. A review. Curr Gene Ther. 2002;2(3):307–22.
  44. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 1992;256(5063):1550–52.
  45. Johnson LG, Olsen JC, Sarkadi B, Moore KL, Swanstrom R, Boucher RC. Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat Genet. 1992;2(1):21–5.
  46. Hooper ML, Subak-Sharpe JH. Metabolic cooperation between cells. Int Rev Cytol. 1981;69:45–104.
  47. Thuringer D, Jego G, Berthenet K, Hammann A, Solary E, Garrido C. Gap junction-mediated transfer of miR-145-5p from microvascular endothelial cells to colon cancer cells inhibits angiogenesis. Oncotarget. 2016;7(19):28160-8.
  48. Lemcke H, Steinhoff G, David R. Gap junctional shuttling of miRNA – A novel pathway of intercellular gene regulation and its prospects in clinical application. Cell Signal. 2015;27(12):2506–14.
  49. Becker DL, Phillips AR, Duft BJ, Kim Y, Green CR. Translating connexin biology into therapeutics. Semin Cell Dev Biol. 2016;50:49–58.
  50. Bavamian S, Pontes H, Cancela J, Charollais A, Startchik S, Van de Ville D, et al. The intercellular synchronization of Ca2+ oscillations evaluates Cx36-dependent coupling. PLoS One 2012;7(7):e41535.
  51. Kahraman S, Okawa ER, Kulkarni RN. Is transforming stem cells to pancreatic beta cells still the holy grail for Type 2 diabetes? Curr Diab Rep. 2016;16(8):70.